NUVB Share Price Performance
US$0
-2.69 (-100.00%)
Price US$0
Fair ValueUS$10.25
Share Pricen/a
Nuvation Bio Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
NUVB Community Narratives
AN
Fair Value US$10.25 15.5% undervalued intrinsic discount
Emerging Glioma Therapy And Lung Cancer Expansion Will Transform Long Term Oncology Franchise
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Emerging Glioma Therapy And Lung Cancer Expansion Will Transform Long Term Oncology Franchise
Catalysts About Nuvation Bio Nuvation Bio is an oncology focused biopharmaceutical company developing and commercializing targeted therapies for difficult to treat cancers. What are the underlying business or industry changes driving this perspective?Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$10.25
15.5% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
151.84% p.a.
Profit Margin
0.012%
Future PE
853.58x
Price in 2028
US$0.13
Trending Discussion
Recently Updated Narratives
AN
Emerging Glioma Therapy And Lung Cancer Expansion Will Transform Long Term Oncology Franchise
Fair Value: US$10.25 15.5% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nuvation Bio Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.63
- 54.26%
- -813.07%
- 16.2%
About NUVB
- Founded
- 2018
- Employees
- 291
- CEO
- WebsiteView website
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
